Relationship between expression of vascular endothelial growth factor in tumor tissue from gastric cancers and chemotherapy effects: Comparison between S-1 alone and the combination of S-1 plus CDDP

Japanese Journal of Clinical Oncology

Volumn 37, Issue 7, 2007, Pages 509-514

  Boku, Narikazu ^a   Ohtsu, Atsushi ^b   Nagashima, Fumio ^c   Shirao, Kuniaki ^d   Koizumi, Wasaburo ^d  

^a SHIZUOKA CANCER CENTER   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c SAITAMA MEDICAL UNIVERSITY   (Japan)

^d KITASATO UNIVERSITY   (Japan)

Author keywords

Gastric cancer; S 1; Vascular endothelial growth factor

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN; VASCULOTROPIN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CANCER TISSUE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROGNOSIS; PROTEIN EXPRESSION; STOMACH ADENOCARCINOMA; STOMACH BIOPSY; STOMACH CANCER; SURVIVAL TIME;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DRUG COMBINATIONS; FLUOROURACIL; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OXONIC ACID; STOMACH NEOPLASMS; TEGAFUR; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34548349319     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hym057     Document Type: Article

References (31)

1. Murad AM, Santiago FF, Petroiann A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993;72:37-41.
2. Cullinan SA, Moertel CG, Wicand HS, O'Connell MJ, Poon MA, Krook SE, et al. Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group. J Clin Oncol 1994;12:412-6.
3. Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 1993;71:3813-18.
4. Ohtsu A, Shimada. Y, Shirao K, Boku N, Hyodo I, Saito H, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 2003;21:54-9.
5. Wils JA, Klein HO, Wagener IN, Bleiberg H, Reis, H, Korsten F, et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin. J Clin Oncol 1991;9:827-31.
6. Kelsen D, Atiq OT, Saltz L, Niedzwiecki D, Ginn D, Chapman D, et al: FAMTX versus etoposide, doxorubicin, and cisplatin: A random assignment trial in gastric cancer. J Clin Oncol 1991;10:541-48.
7. Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Custem E, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Cli Oncol 2000;18:2648-57.
8. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, et al. Randomized trial corparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997;15:261-7.
9. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late phase II study of novel oral fluoropyrimidine anticancer chug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998;34:1715-20.
10. Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 2000;58:191-7.
11. Koizumi W, Tanabe S, Saigenji K, Ohtsu A, Boku N, Nagashima F, et al. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 2003;89:2207-12.
12. Boku N, Chin K, Hosokawa K, Ohtsu A, Tajiri H, Yoshida S, et al. Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum. Clin Cancer Res 1998;4:1469-74.
13. Nagashima F, Boku N, Ohtsu A, Yoshida S, Hasebe T, Ochiai A, et al. Biological markets as a predictor for response and prognosis of unresectable gastric cancer patients treated with irinotecan and cisplatin. Jpn J Clin Oncol 2005;35:714-19.
14. Boku N, Ohtsu A, Yoshida S, Shirao K, Shimada Y, Hyodo I, et al. Significance of biological markers for predicting prognosis and selecting chemotherapy regimens of advanced gastric cancer patients between continuous infusion of 5-FU and a combination of 5-FU and cisplatin. Jpn J Clin Oncol 2007;37:275-81.
15. Nagashima F, Ohtsu A, Yoshida S, Ito K. Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer, Gastic Cancer 2005;8:6-11.
16. Japanese Research Society for Gastric Canper. Japanese Classification of Gastric Carcinoma, 1st Engl. edn. Tokyo: Kanehara 1995.
17. Hyodo I, S-1 combined with weekly dosing of cisplatin for metastatic gastric cancer. Gan To Kagaku Ryoho 2006;33 (Suppl 1):64-7 (in Japanese).
18. Ajani JA, Lee FC, Singh DA, Haller DG, Lenz HJ, Benson AB III, et al. Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006;24:663-7.
19. Connolly DT, Heuvelman DM, Nelson R, Olander JV, Eppley BL, Delfino JJ, et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 1989;84:1470-8.
20. Dvorak HF, Orenstein NS, Carvalho AC, Churchill WH, Dvorak AM, Galli SJ, et al. Induction of a fibrin-gel investment: An early event in line 10 hepatocarcinoma growth mediated by tumor secreted products. J Immmunol 1979;122:166-74.
21. Ellis LM. Angiogenesis and its role in colorectal tumor and metastasis formation. Semin Oncol 2004;6 (Suppl 17):3-9.
22. Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M, et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996;77:858-63.
23. Gasparini G, Toi M, Gion M, Verderio P, Dittadi R, Hanatani M, et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 1997;89:139-47.
24. Takahashi Y, Tucker SL, Kitadai Y, Koura AN, Bucana CD, Cleary KR, ct al. Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch Surg 1997;132:541-6.
25. Itakura J, Ishiwata T, Friess H, Fujii H, Matsumoto Y, Buchler MW, et al. Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin Cancer Res 1997;3:1309-16.
26. Kaya M, Wada T, Akatsuka T, Kawaguchi S, Nagoya S, Shindo M, et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res 2000;6:572-7.
27. Shih CH, Ozawa S, Ando N, Ueda M, Kitajima M. Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus. Clin Cancer Res 2000;6:1161-8.
28. Smith BD, Smith GL, Carter D, Sasaki CT, Haffty BG. Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharytigeal squamous cell carcinoma. J Clin Oncol 2000;18:2046-52.
29. Yasui W, One N, Aung PP, Matsumura S, Shutoh M, Nakayama H. Molecular-pathological prognostic factors of gastric cancer: A review. Gastric Cancer 2005;8:86-94.
30. Juttner S, Wissmann C, Jons T, Vieth M, Hertel J, Gretschel S, et al. Vascular endothelial growth factor-D and its receptor VEGFR-3: Two novel independent prognostic markers in gastric adenocarcinoma. J Clin Oncol 2006;24:228-40.
31. Takiuchi H, Hirata I, Kawabe SI, Egashira Y, Katsu K. Immunohistochemical expression of vascular endothelial growth factor can predict response to 5-fluorouracil and cisplatin in patients with gastric adenocarcinoma. Oncol Rep 2000;7:841-6.